Annals of Oncology 11:743-747, 2000
© 2000 European Society for Medical Oncology
other |
Acute deterioration of Charcot-Marie-Tooth disease IA (CMTIA) following 2 mg of vincristine chemotherapy
1Department of Hematology & Oncology, University of Regensburg Regensburg, Germany
2Department of Pathology, University of Regensburg Regensburg, Germany
3Department of Neurology, University of Regensburg Regensburg, Germany
Correspondence to: G. Hildebrandt, MD, Department of Hematology & Oncology, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. E-mail: gerhard.hildebrandt{at}klinik.uni-regensburg.de
Background: Severe up to life-threatening neuropathy has been observed in patients with hereditary neuropathies receiving vincristine.
Case report: A 52-year-old female painter suffering from high-grade non-Hodgkin's lymphoma (stage IVB) was treated with a total of 4 mg of vincristine during two courses of CHOP chemotherapy (cyclophosphamide, vincristine, adriamycin, prednisone). At onset of treatment no neurological problems were reported. There was good lymphoma response to chemotherapy. At the same time, however, the patient gradually developed dysphagia, dysarthria, muscular weakness of both lower and upper extremities, areflexia, paraesthesia of the fingertips and bilateral sensory impairment of feet and lower legs. These symptoms continually worsened over a period of seven weeks until she was unable to walk or to perform her work. Electrophysiological studies showed peripheral axonal and demyelinative sensorimotor neuropathy in correlation to histological findings. Molecular analysis revealed 17p11.2 duplication typical for Charcot-Marie-Tooth disease IA. While continuing chemotherapy without the use of vincristine the patient's neurologic symptoms slowly recovered within six months.
Conclusion: Prior to administration of vincristine family and patient history as well as physical examination should be performed carefully to look for underlying hereditary neuropathy. For those patients with a clinical history or symptoms suggestive for CMT nerve conduction velocity studies and on an individual base even molecular genetic analysis are neccessary to prevent serious neurologic complications.
Charcot-Marie-Tooth disease, chemotherapy, hereditary motor and sensory neuropathy, PMP22, vincristine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Orejana-Garcia, J. Pascual-Huerta, and A. Perez-Melero Charcot-Marie-Tooth Disease and Vincristine J Am Podiatr Med Assoc, May 1, 2003; 93(3): 229 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chaudhry, M. Chaudhry, T.O. Crawford, E. Simmons-O'Brien, and J.W. Griffin Toxic neuropathy in patients with pre-existing neuropathy Neurology, January 28, 2003; 60(2): 337 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kalfakis, M. Panas, G. Karadima, P. Floroskufi, N. Kokolakis, and D. Vassilopoulos Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment Neurology, November 12, 2002; 59(9): 1470 - 1471. [Full Text] [PDF]
|
|